Vir Biotechnology, Inc.
VIR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.01 | -1.47 | -0.04 |
| FCF Yield | -45.36% | -59.31% | 47.53% | -1.28% |
| EV / EBITDA | -1.72 | -1.92 | 3.14 | 12.26 |
| Quality | ||||
| ROIC | -45.53% | -38.15% | 24.82% | 25.02% |
| Gross Margin | -545.03% | -564.69% | 61.57% | 53.09% |
| Cash Conversion Ratio | 0.86 | 1.27 | 3.22 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -64.19% | -57.15% | 188.56% | 1,054.97% |
| Free Cash Flow Growth | 43.32% | -150.17% | 2,398.43% | 64.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.18 | -0.86 | -0.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3.87 | -4.04 | -3.77 | 252.96 |